Search research articles
Contact Us
Filters
Showing results (1-10 of 47) with videos related to
Page
of 5
Sort By:
The British Journal of Surgery
|
September 1, 1992
Smoking predisposes to parotid adenolymphoma
M Cadier, G Watkin, M Hobsley
The British Journal of Surgery
|
October 1, 1995
Critical limb ischaemia in patients over 80 years of age: options in a district general hospital
W V Humphreys, F Evans, G Watkin, et al.
The British Journal of Surgery
|
January 1, 1991
Further evaluation of radical surgery following radiotherapy for advanced parotid carcinoma
N C Gallegos, G Watkin, H P Cook, et al.
Cancer Investigation
|
June 17, 2006
Metastatic basal cell carcinoma: complete response to chemotherapy and associated pure red cell aplasia
Benedito A Carneiro, William G Watkin, Uday K Mehta, et al.
Pain Medicine (Malden, Mass.)
|
July 31, 2007
Duloxetine for the management of diabetic peripheral neuropathic pain: response profile
Yili L Pritchett, Bill H McCarberg, John G Watkin, et al.
BMC Geriatrics
|
December 9, 2004
Duloxetine for the long-term treatment of major depressive disorder in patients aged 65 and older: an open-label study
Madelaine M Wohlreich, Craig H Mallinckrodt, John G Watkin, et al.
BMC Psychiatry
|
January 6, 2005
Duloxetine in the treatment of Major Depressive Disorder: a comparison of efficacy in patients with and without melancholic features
Craig H Mallinckrodt, John G Watkin, Chaofeng Liu, et al.
Depression and Anxiety
|
July 18, 2006
Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation
Madelaine M Wohlreich, Craig H Mallinckrodt, Apurva Prakash, et al.
Archives of Pathology & Laboratory Medicine
|
August 1, 1989
Amniotic band syndrome. Report of two cases and review of the literature
J D Seidman, S L Abbondanzo, W G Watkin, et al.
Journal of Psychiatric Research
|
November 8, 2005
Duloxetine for the treatment of major depressive disorder: a closer look at efficacy and safety data across the approved dose range
Craig H Mallinckrodt, Apurva Prakash, Anne C Andorn, et al.
Page
of 5
Search research articles
Search
Showing results (1-10 of 47) with videos related to
Sort By:
Page
of 5
The British Journal of Surgery
|
September 1, 1992
Smoking predisposes to parotid adenolymphoma
M Cadier, G Watkin, M Hobsley
The British Journal of Surgery
|
October 1, 1995
Critical limb ischaemia in patients over 80 years of age: options in a district general hospital
W V Humphreys, F Evans, G Watkin, et al.
The British Journal of Surgery
|
January 1, 1991
Further evaluation of radical surgery following radiotherapy for advanced parotid carcinoma
N C Gallegos, G Watkin, H P Cook, et al.
Cancer Investigation
|
June 17, 2006
Metastatic basal cell carcinoma: complete response to chemotherapy and associated pure red cell aplasia
Benedito A Carneiro, William G Watkin, Uday K Mehta, et al.
Pain Medicine (Malden, Mass.)
|
July 31, 2007
Duloxetine for the management of diabetic peripheral neuropathic pain: response profile
Yili L Pritchett, Bill H McCarberg, John G Watkin, et al.
BMC Geriatrics
|
December 9, 2004
Duloxetine for the long-term treatment of major depressive disorder in patients aged 65 and older: an open-label study
Madelaine M Wohlreich, Craig H Mallinckrodt, John G Watkin, et al.
BMC Psychiatry
|
January 6, 2005
Duloxetine in the treatment of Major Depressive Disorder: a comparison of efficacy in patients with and without melancholic features
Craig H Mallinckrodt, John G Watkin, Chaofeng Liu, et al.
Depression and Anxiety
|
July 18, 2006
Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation
Madelaine M Wohlreich, Craig H Mallinckrodt, Apurva Prakash, et al.
Archives of Pathology & Laboratory Medicine
|
August 1, 1989
Amniotic band syndrome. Report of two cases and review of the literature
J D Seidman, S L Abbondanzo, W G Watkin, et al.
Journal of Psychiatric Research
|
November 8, 2005
Duloxetine for the treatment of major depressive disorder: a closer look at efficacy and safety data across the approved dose range
Craig H Mallinckrodt, Apurva Prakash, Anne C Andorn, et al.
Page
of 5